|
注册号: Registration number: |
ChiCTR2500115050 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-22 10:34:34 |
|
注册时间: Date of Registration: |
2025-12-22 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
碘伏消毒凝胶用于治疗创面感染的安全性与有效性的前瞻性研究 |
|
Public title: |
A prospective study evaluating the safety and efficacy of povidone-iodine disinfectant hydrogel for the treatment of wound infections |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
碘伏消毒凝胶用于治疗创面感染的安全性与有效性的前瞻性研究 |
|
Scientific title: |
A prospective study evaluating the safety and efficacy of povidone-iodine disinfectant hydrogel for the treatment of wound infections |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨梦蝶 |
研究负责人: |
蔡蕴敏 |
|
Applicant: |
Mengdie Yang |
Study leader: |
Yunmin Cai |
|
申请注册联系人电话: Applicant telephone: |
+86 152 5654 5014 |
研究负责人电话:
Study leader's |
+86 189 3081 9161 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
mdyang@linglecn.com |
研究负责人电子邮件: Study leader's E-mail: |
cymajj@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国广东省中山市翠亨新区未来大道50号GMP厂房2栋2层 |
研究负责人通讯地址: |
中国上海市金山区龙航路1508号 |
|
Applicant address: |
Building 2, Floor 2, GMP Factory, No. 50, Futian Road, Cuiheng New District, Zhongshan, Guangdong, China |
Study leader's address: |
No. 1508 Longhang Road, Jinshan District, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
528400 |
研究负责人邮政编码: Study leader's postcode: |
528400 |
|
申请人所在单位: |
中山光禾医疗科技有限公司 |
||
|
Applicant's institution: |
ZhongShan Guanghe Medical Technology Co., Ltd. |
||
|
研究负责人所在单位: |
复旦大学附属金山医院 |
||
|
Affiliation of the Leader: |
Jinshan Hospital of Fudan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
JIEC 2025-S75 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属金山医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Jinshan Hospital of Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-11-25 00:00:00 | ||
|
伦理委员会联系人: |
王淑颖 |
||
|
Contact Name of the ethic committee: |
Shuying Wang |
||
|
伦理委员会联系地址: |
中国上海市金山区龙航路1508号 |
||
|
Contact Address of the ethic committee: |
No. 1508 Longhang Road, Jinshan District, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 57039818 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
复旦大学附属金山医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Jinshan Hospital of Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国上海市金山区龙航路1508号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 1508 Longhang Road, Jinshan District, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中山光禾医疗科技有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
ZhongShan Guanghe Medical Technology Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
创面感染 |
||||||||||||||||||||||
|
Target disease: |
Wound infection |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
通过将碘伏消毒凝胶用于感染创面,评价使用7天后,该产品用于治疗创面感染的有效率 |
||||||||||||||||||||||
|
Objectives of Study: |
By applying povidone-iodine disinfectant hydrogel to infected wounds, evaluate the effectiveness rate of this product in treating wound infections after 7 days of use. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.处于妊娠期或者哺乳期的女性; 2.感染/坏死累及深筋膜、肌肉等深层软组织,或形成深在窦道或面部; 3.入组前未做细菌培养者; 4.全身感染表现明显,或全身病情较重,需要系统用药或手术干预; 5.既往肿瘤病史或需使用免疫抑制剂者; 6.有严重心血管系统、肝脏、肾脏或血液系统疾病者; 7.有精神分裂症病史或其他严重精神疾病史、药物或酒精滥用; 8.已知对本产品过敏的受试者; 9.最近3个月参加过其他临床试验; 10.研究者认为研究期间不能遵循方案要求完成研究的受试者; 11. 研究者认为受试者不适合参与本研究的任何情况 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Women who are pregnant or lactating; 2.Infection/necrosis involves deep soft tissues such as the deep fascia and muscles, or forms a deep sinus tract,or face; 3.Subjects who did not undergo bacterial culture before enrollment; 4.Subjects with obvious manifestations of systemic infection, or those with severe systemic conditions that require systemic medication or surgical intervention; 5.Subjects with a history of previous tumors or those who require the use of immunosuppressants; 6.Subjects with severe diseases of the cardiovascular system, liver, kidneys, or hematological system; 7.Subjects with a history of schizophrenia, a history of other severe mental illnesses, or a history of drug or alcohol abuse 8.Subjects with a known allergy to this product; 9.Subjects who have participated in other clinical trials within the recent 3 months; 10.Subjects whom the investigator deems unable to comply with the protocol requirements to complete the study during the study period; 11.Researchers consider any situation in which the participants are not suitable for participating in this study |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-01-01 00:00:00 至 To 2026-07-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |